The Role of Cetrotide Acetate in Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in Oocyte Donors

Completed · Not applicable

Conditions studied: Ovarian Hyperstimulation Syndrome

In brief

This pilot study aims to address whether the prophylactic use of Cetrorelix Acetate after a long gonadotropin-releasing hormone (GnRH) agonist protocol post-hCG (human chorionic gonadotropin) administration can significantly reduce the incidence of OHSS in oocyte donors.

Key facts

Study ID

NCT00867659

Run by

Virginia Center for Reproductive Medicine

People needed

20

Starts

2009-03-01

Expected to finish

2011-10-01

Last updated by the study team

2013-03-27

Who can join

Age: 19 and older, up to 32. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Prospective donors with BMIs between 19 and 28,
• Those with normal FSH levels and good antral follicle counts between 19-28 years of age, AND
• Donors would have passed all the required testing as mandated by VCRM and the FDA.

You may not qualify if…

• Oocyte donors exceeding a BMI of > 28,
• Those with any communicable diseases,
• Those with low antral follicle counts and small ovarian volumes,
• Those with elevated FSH levels,
• Those with positive sickle cell screen or cystic fibrosis screening,
• Smokers, OR
• Donors who are unable or unwilling to follow the research protocols.

Where it is running

• Virginia Center for Reproductive Medicine — Reston, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.